European public and venture funding flowed to two early biotech platforms this week. German research teams won €3.2 million from the federal Go‑Bio Next program to develop a DNAzyme cancer therapy platform (DNAmazing), partnering university labs with lipid‑nanoparticle and oligonucleotide manufacturers to push a lead DNAzyme toward clinical testing and company spin‑out. Separately, Stockholm‑based CubaseBio closed €5.9 million to commercialize 3D spatial transcriptomics for organoids and complex samples, blending EIC non‑dilutive support with private financing led by Voima Ventures and Nordic Science Investments. CubaseBio’s technology builds on DNA microscopy and aims to measure transcriptomes in three dimensions for drug discovery and disease research. Both awards signal continued public and VC appetite for platform technologies that lower barriers to translational research and therapeutic development across Europe.